Next Article in Journal
Smad3 Deficiency Ameliorates Hepatic Fibrogenesis through the Expression of Senescence Marker Protein-30, an Antioxidant-Related Protein
Next Article in Special Issue
Radiation-Sensitising Effects of Antennapedia Proteins (ANTP)-SmacN7 on Tumour Cells
Previous Article in Journal
Tackling Structures of Long Noncoding RNAs
Previous Article in Special Issue
MicroRNAs and Triple Negative Breast Cancer
Int. J. Mol. Sci. 2013, 14(12), 23685-23699; doi:10.3390/ijms141223685
Article

Prognostic Discrimination Using a 70-Gene Signature among Patients with Estrogen Receptor-Positive Breast Cancer and an Intermediate 21-Gene Recurrence Score

1
, 1
, 1
, 2
, 3
, 3
, 1,*  and 4
Received: 30 August 2013; in revised form: 15 November 2013 / Accepted: 19 November 2013 / Published: 4 December 2013
(This article belongs to the Special Issue Molecular Bases of Cancer Research)
View Full-Text   |   Download PDF [987 KB, uploaded 19 June 2014]   |   Browse Figures
Abstract: The Oncotype DX® recurrence score (RS) predictor has been clinically utilized to appropriately select adjuvant chemotherapy for patients with estrogen receptor (ER)-positive early breast cancer. However, the selection of chemotherapy for patients with intermediate RSs remains controversial. We assessed the prognostic value of a 70-gene signature (70GS) among patients with ER-positive breast cancer and intermediate RSs. In addition, we sought to identify genes associated with poor 70GS scores based on gene expression profiling (GEP). GEP was performed using gene expression data from 186 patients with ER-positive breast cancer. The RS and 70GS score were calculated on the basis of GEP. Among 186 patients, 82 ER-positive patients with intermediate RSs were identified. These patients were stratified by 70GS, overall survival (OS) significantly differed according to 70GS (p = 0.013). In a supervised hierarchical analysis according to 70GS, the expression of several representative genes for cell proliferation was significantly higher in the poor 70GS cluster than in the good 70GS cluster. Furthermore, among these patients, FOXM1, AURKA, AURKB, and BIRC5 displayed prognostic significance for OS. In conclusion, 70GS can help to discriminate survival differences among ER-positive patients with intermediate RSs. FOXM1, AURKA, AURKB, and BIRC5, are associated with poor 70GS scores.
Keywords: breast cancer; estrogen receptor; recurrence score; 70-gene signature; FOXM1; AURKA; AURKB; BIRC5 breast cancer; estrogen receptor; recurrence score; 70-gene signature; FOXM1; AURKA; AURKB; BIRC5
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Ahn, S.G.; Lee, H.M.; Lee, H.W.; Lee, S.A.; Lee, S.-R.; Leem, S.-H.; Jeong, J.; Chu, I.-S. Prognostic Discrimination Using a 70-Gene Signature among Patients with Estrogen Receptor-Positive Breast Cancer and an Intermediate 21-Gene Recurrence Score. Int. J. Mol. Sci. 2013, 14, 23685-23699.

AMA Style

Ahn SG, Lee HM, Lee HW, Lee SA, Lee S-R, Leem S-H, Jeong J, Chu I-S. Prognostic Discrimination Using a 70-Gene Signature among Patients with Estrogen Receptor-Positive Breast Cancer and an Intermediate 21-Gene Recurrence Score. International Journal of Molecular Sciences. 2013; 14(12):23685-23699.

Chicago/Turabian Style

Ahn, Sung G.; Lee, Hak M.; Lee, Hak W.; Lee, Seung A.; Lee, Se-Ra; Leem, Sun-Hee; Jeong, Joon; Chu, In-Sun. 2013. "Prognostic Discrimination Using a 70-Gene Signature among Patients with Estrogen Receptor-Positive Breast Cancer and an Intermediate 21-Gene Recurrence Score." Int. J. Mol. Sci. 14, no. 12: 23685-23699.


Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert